Nexus Pharmaceuticals Launches Methylene Blue Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, LLC proudly announces the launch of Methylene Blue Injection, USP. Methylene Blue Injection is indicated for the treatment of methemoglobinemia – a condition that affects the blood’s ability to carry oxygen.

“The launch represents a vital addition to Nexus’ growing portfolio of life-saving and difficult-to-manufacture medications,” said Usman Ahmed, CEO of Nexus Pharmaceuticals. “Methylene Blue is a critical drug in emergency care, and we’re proud to contribute to the FDA-approved supply.”

Nexus’ Methylene Blue is available in cartons of five, single-dose 10 mL vials (5 mg/mL) (0.5%). Order through your Wholesaler or from Customer Service at (888) 806-4606.

Unit of Sale NDC: 14789-0119-05

- Cencora – 10299117
- Cardinal – 5982525
- McKesson – 3029428
- Morris & Dickson – 609628

About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250522266031/en/

Media Contact:
Grace Conroy
[email protected]
(847) 527-7490

Source: Nexus Pharmaceuticals, LLC

You May Also Be Interested In

• Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
• Little Canada Rebrands as Pocket Planet Canada: A New Era of Immersive Entertainment for Toronto
• TELESUR AND LIBERTY NETWORKS STRENGTHEN PARTNERSHIP FOR A MORE RESILIENT DIGITAL SURINAME